Program
eneboparatide
Also written as “AZP-3601”.
Its studies are mostly in Hypoparathyroidism, led by AstraZeneca.
Furthest: phase 3, since Mar 9, 20232 company-led studies, 1 open or running
Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| AstraZeneca | 21 open or running | phase 3since Mar 9, 2023 | Jan 7, 2022 | none ahead |
- Named in AstraZeneca’s own pipeline as
eneboparatide
, phase 3, as of Oct 30, 2026 (source).
Also a collaborator on its studies: amolyt-pharma.
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
- Jan 7, 2022First study: phase 2 study in Chronic HypoparathyroidismFirst studyNCT05239221 · 132 enrolled · Hungary, Netherlands
- Mar 9, 2023Phase 3 study in Endocrine System DiseasesNCT05778071 · 165 enrolled · United States, Canada, Denmark and more
TargetBeta
“A Phase 3 Multicenter, Randomized, Placebo-controlled, Double-blind Study to Evaluate the Efficacy and Safety of Eneboparatide (AZP-3601), a Parathyroid Hormone Receptor Agonist, in Patients With Chronic Hypoparathyroidism (CALYPSO)”study text, read by Claude · the study
Other programs on PTH1R
| Program | Company | Furthest phase | Studies |
|---|---|---|---|
| Palopegteriparatiderule | ascendis-pharma-bone-diseases-a-s | phase 3 | 5 |
Studies
All 2 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Primary completion | Size |
|---|---|---|---|---|
| NCT05778071Endocrine System Diseases · United States, Canada, Denmark and more | 3 | Active, not recruiting | Nov 15, 2024 | 165 |
| NCT05239221Chronic Hypoparathyroidism · Hungary, Netherlands | 2 | Completed | Aug 23, 2022 | 132 |
How it is read
Names in the registry
- “eneboparatide”, 1 entry
- “AZP-3601”, 1 entry
Conditions, from the studies’ own filings
- Hypoparathyroidism, 2 studies
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.